When does skyrizi patent expire?

Who owns the Skyrizi patent and when does it expire?

Skyrizi, an innovative psoriasis and inflammatory disease treatment developed by AbbVie, uses a proprietary molecule called risankizumab. This biologic medication has shown significant benefits for patients suffering from moderate to severe plaque psoriasis and other diseases.

Key Patent Holders: AbbVie Inc. and AbbVie Biotechnology Ltd. [1]

While there are several patents associated with Skyrizi, the primary patent holder is AbbVie Inc. and AbbVie Biotechnology Ltd. According to the FDA website and intellectual property trackers like DrugPatentWatch.com [2], the patent exclusivity for Skyrizi's main formulation will last until 2029.

Timeline and Patent Life Cycle:

- Initial FDA approval: 2019
- Patent application filing date: Not publicly available
- AbbVie has filed various patent applications related to Skyrizi, which provide protection for different aspects of the drug's formulation and manufacturing

Exclusivity and Competition:

The expiry of Skyrizi's patent could potentially open up the market to biosimilars and generic versions of the medication. As patent exclusivity expires in 2029, other pharmaceutical companies can begin applying for biosimilar or generic versions of Skyrizi.

[1] Source: FDA.gov; [2] Source: DrugPatentWatch.com (www.drugpatentwatch.com);